India’s Biocon To Buck Trend, Make R&D Wholly Owned Subsidiary
This article was originally published in PharmAsia News
Indian biotech Biocon is rejecting the path of many of its pharmaceutical colleagues and making its research and development unit into a wholly owned subsidiary. Other Indian pharmaceutical firms have been spinning off their R&D operations into separate companies in recent years, but a source said Biocon management considers R&D an integral part of its business. Analysts also say the move, scheduled for later this year, would help Biocon reduce its generics risk profile. (Click here for more
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.